AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

USA: The management of fracture-related infections (FRIs) often involves prolonged antibiotic therapy, with intravenous (IV) ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Pregnant women with obesity face an increased risk of complications, including the need for a cesarean section, which carries ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Our study, involving 61 immunocompentent patients with primary vertebral osteomyelitis, illustrates that switching to an oral antibiotic regimen after 2 weeks of intravenous therapy may be safe ...